Arrowhead Pharmaceuticals, Inc. (ARWR) Shares Down 9.6%

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shares fell 9.6% on Monday . The company traded as low as $3.04 and last traded at $3.41. 1,276,293 shares traded hands during mid-day trading, an increase of 24% from the average session volume of 1,027,980 shares. The stock had previously closed at $3.11.

A number of research firms recently weighed in on ARWR. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $1.80.

The company’s 50-day moving average price is $2.23 and its 200 day moving average price is $1.85. The stock’s market capitalization is $257.22 million.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. The firm had revenue of $9.34 million during the quarter, compared to analyst estimates of $5.29 million. On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post ($0.42) earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its stake in shares of Arrowhead Pharmaceuticals by 3.7% in the 1st quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock worth $581,000 after acquiring an additional 11,099 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Arrowhead Pharmaceuticals by 18.0% in the 4th quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 17,201 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Arrowhead Pharmaceuticals by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after acquiring an additional 21,654 shares in the last quarter. Virtu KCG Holdings LLC grew its stake in shares of Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 53,215 shares in the last quarter. Finally, UBS Asset Management Americas Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 414.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 53,500 shares in the last quarter. Hedge funds and other institutional investors own 20.63% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Arrowhead Pharmaceuticals, Inc. (ARWR) Shares Down 9.6%” was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.thestockobserver.com/2017/09/13/arrowhead-pharmaceuticals-inc-arwr-shares-down-9-6.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply